Literature DB >> 31645888

Acute myeloid leukaemia presenting as acute liver failure-a case report and literature review.

Kai Sun1, Ryan J Reynolds1, Tiffany G Sheu2, Jessica A Tomsula2, Lara Colton1,3, Lawrence Rice1,3.   

Abstract

A 75-year-old woman presented with rapidly progressive fatigue, abdominal pain and jaundice. Physical examination revealed tender abdomen and splenomegaly. Magnetic resonance cholangiogram showed marked hepatomegaly, splenomegaly and scattered nodules or masses in the liver and spleen. The patient expired from multiorgan failure. Autopsy revealed infiltration of the liver, spleen and bone marrow by acute myeloid leukaemia. © the authors; licensee ecancermedicalscience.

Entities:  

Keywords:  acute liver failure; acute myeloid leukaemia; obstructive jaundice

Year:  2019        PMID: 31645888      PMCID: PMC6786829          DOI: 10.3332/ecancer.2019.960

Source DB:  PubMed          Journal:  Ecancermedicalscience        ISSN: 1754-6605


Introduction

In patients presenting with acute liver failure (ALF), acute myeloblastic leukaemia (AML) is extraordinarily rare and is associated with very high mortality. We cared for a patient who presented with acute hepatic failure and was diagnosed with AML on autopsy (albeit suspected immediately pre-mortem). We review the literature to gain insights into this problem and how outcomes might be improved.

Case presentation

A 75-year-old woman presented to another hospital with fatigue, right upper quadrant abdominal pain and jaundice, was evolving over several days. She denied fever, sick contacts, recent infectious symptoms, recent travel or new medications. Past medical history was remarkable only for moderate Parkinson’s disease. Medications were aspirin, calcium-vitamin D3 and rasagiline. She was afebrile and jaundiced. Haemoglobin was 8.9 g/dL; white blood cells 6.35 k/uL with 63% neutrophils, 21% lymphocytes and 13% monocytes; platelets 30 k/uL; alkaline phosphatase 92 U/L; aspartate aminotransferase (AST) 62 U/L; alanine aminotransferase (ALT) 104 U/L and total bilirubin 4.5 with 2.4 mg/dL direct fraction. Tests for Epstein–Barr virus, cytomegalovirus, hepatitis and human immunodeficiency viruses were negative. Autoimmune workup was negative, including anti-nuclear antibodies, anti-mitochondrial antibody, anti-Smith antibody and liver-kidney microsomal antibody. Magnetic resonance cholangiogram showed marked hepatomegaly, moderate splenomegaly and nodular areas of decreased T2-weighted signal within the liver and spleen parenchyma. She clinically deteriorated over a few days. On transfer to Houston Methodist Hospital, she appeared acutely ill and moderately confused. The abdomen was distended, tense and tender in the right upper quadrant; the spleen was palpably enlarged. The white blood cell count remained 6.29 k/uL with 75% neutrophils, 18% lymphocytes and 5% monocytes; haemoglobin 7.9g/dL; platelets 9 k/uL; alkaline phosphatase 92 U/L, AST 34 U/L and ALT 79 U/L; total bilirubin 16.4 mg/dL; direct bilirubin more than 10 mg/dL; lactate dehydrogenase (LDH) 123 U/L and prothrombin time 21.2 s, internationalised ratio 1.8, partial thromboplastin time 36, D-dimer 3.41 and fibrinogen 159 mg/dL. Florid encephalopathy rapidly ensued, as AST increased to 1,669, ALT to 518, total bilirubin to 19.8, along with acute renal failure, worsening coagulopathy and severe metabolic acidosis. A haematology consultant noted rare large blast cells on the peripheral smear (3 of 200 cells, Figure 1); peripheral blood flow cytometry did not detect these. The patient expired within few days of initial presentation before planned liver and bone marrow biopsies could be performed.
Figure 1.

Peripheral smear.

A limited autopsy of the liver, spleen and bone marrow revealed gross hepatosplenomegaly with diffusely mottled hepatic parenchyma and variably soft and firm red-black nodular spleen. Microscopic examination of the liver and spleen found effacement of the normal architecture by a diffuse neoplastic infiltrate (Figure 2). Residual hepatocytes were necrotic. The neoplastic cells had scant cytoplasm, immature nuclear chromatin and moderate nuclear pleomorphism. Bone marrow (Figure 3) was hypercellular (80%) with expansion by neoplastic cells. While few residual erythroid and megakaryocytic elements were identifiable, there were no maturing myeloid precursors. Immunohistochemical stains confirmed the myeloid lineage of the neoplastic cells (strong positive myeloperoxidase) which also expressed monocytic (lysozyme) and erythroid (E-cadherin) markers. Subclassification of the AML was limited by cellular degeneration, so the process was classified as acute myeloid leukaemia, not otherwise specified.
Figure 2.

Microscopic examination of the liver.

Figure 3.

Microscopic examination of bone marrow.

Discussion

ALF is a life-threatening disease with high mortality rate [1]. The most common causes of ALF are drugs (acetaminophen is most common [2]) and viral infections [3]. Neoplastic infiltration as a cause of ALF is rare. In a large single centre study performed by Rowbotham et al. [4], only 18 out of 4,020 patients (0.44%) had their ALF attributable to neoplastic infiltration. Rich et al. [5] found only 27 of 1,910 such cases (1.4%). The most common malignancies in those studies were lymphoma (41%–79%) and metastatic breast cancer (30%), whereas only two patients had ALF from acute leukaemia. AML as a cause of ALF is reported far less commonly than acute lymphoblastic leukaemia (ALL) in children [6-8] and in adults [9-13] but has been described in several case reports. The first report of ALF due to AML was by Buchler and Cline [14] who described a young female with initially vaginal lymphoma; no details of the AML were provided in the case report. Seven subsequent cases of AML presenting as obstructive jaundice or ALF without distinguishable obstructive masses have been reported [12, 15–20] (see Table 1). All patients had abnormal blood counts that were reflected as anaemia and/or thrombocytopenia and/or leukocytosis. Blasts were seen on peripheral smears in five of seven patients. Five of seven patients had liver and/or spleen enlargement detected on physical examination, abdominal imaging or autopsy.
Table 1.

Summary of case reports of AML presenting as obstructive jaundice or ALF.

AuthorsAge/GenderCBCLiver functionLDHSmearBone marrowLiver biopsyImagingOutcome
Goor et al. [15]36/MHepatomegaly on examWBC 4.640% blastsHgb 12.5Plt 176Tbil 3.5AST 350ALT 360AMLNot doneUS: dilatation of intrahepatic bile duct, normal size CBD and thickening of the gallbladder wallCR after chemo
Wandroo et al. [16]40/MWBC 23.5(N 26.7% L 15.7%, Mono 52.8%, E 2%, blasts 0.8%)Hgb 11.4Plt 75Tbil 4.68AST 142Dysplastic monocytes with occasional monoblastsIncreased number of myeloid and monocytic cells with few blastsDiffuse sinusoidal infiltration by a pleomorphic population of cells, mostly consisting of neutrophil and monocytes, with some immature blastsCT: hepatosplenomegaly; altered echogenicity of the liver but normal biliary ductsCR after chemo
Sobotka et al. [20]66/FWBC 3.1Hgb 8.6Plt 18Tbil 3.4Dbil 1.7AST 38ALT 26Dry tapDiffuse infiltration of the liver with left-shifted erythroid precursors and hepatocellular cholestasisMRI: coarse echotexture of the liver, normal bile ductsDeath
Rajesh et al. [17]32/MWBC 10.2(N 65%, L 13%, Mono 20%, E 2%, B 1%)Hgb 11.9Plt 289Tbil 24.9Dbil 14.7AST 52ALT 60Blasts75% peroxidase-positive myeloid blasts with large number of eosinophilsCT: hepatomegaly, dilatation of intrahepatic ducts and CBDDeath
Mathews et al. [18]66/FWBC 12.4Plt 63AST 49ALT 73No cholestasisFew circulating blastsConfirmed AMLHepatic sinusoidal infiltration with AMLMRI: an 11 mm T2 hyperintense lesion in the posterior dome of the liverCR after induction chemo but death after relapse
Anderson et al. [12]30/FWBC 114Hgb 13.6Plt 70Tbil 12.9AST 5,0805,835Leukoerythroblastic film, predominantly monoblastsAutopsy: confluent necrosis with multiacinar collapse and widespread infiltration by myeloid leukaemic cellsUS: splenomegaly; normal liver with no biliary dilatationDeath
Eisen et al. [19]74/MWBC 8.76(N 79%, L 6.5%, Mono 12%)Hgb 14.7Plt 138Tbil 8.4Dbil 6.5AST 859ALT 4433,357No blastsInfiltration by myeloid blast cells, positive to myeloperoxidase and vimentinAutopsy: enlarged liver with multiple white and red nodules and numerous cystic- like areas and necrosisCT: hypodense areas in the liverDeath
Our case75/FWBC 6.35(N 63.3%, L 20.5%, M 13.4%)Hgb 8.9Plt 30Tbil 4.5Dbil 2.4AST 62ALT 104Rare blastsIncreased cellularity, diffuse infiltration by neoplastic cells and complete loss of myeloid maturationAutopsy: diffuse infiltration of the liver by neoplastic cells and loss of normal structuresMRI: hepatomegaly and moderate splenomegaly; scattered nodular or mass-like areas of decreased T2-weighted signal within the hepatic and splenic parenchymaDeath

All laboratory values are of first encounters. Abbreviations and units: M, male; F, female; WBC, white blood cell X 109/L; Hgb, haemoglobin g/dl; Plt, platelets X 109/L; N, neutrophils; L, lymphocytes; E, eosinophils; B, basophils; Tbil, total bilirubin in mg/dL; AST, aspartate aminotransferase U/L; DBil, direct bilirubin in mg/dL; ALT, alanine aminotransferase U/L; LDH, lactate dehydrogenase U/L; US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging; CBD, common bile duct

In those cases, the ALF was manifest as cholestatic, hepatocellular or a mixed pattern, but hepatic sinusoidal infiltration was universally seen on liver biopsies. The patients who presented with very high bilirubin also had hepatocyte necrosis. We suspect that the liver damage first starts with hepatic sinusoidal infiltration causing ischaemia, then progresses to liver failure when the damage leads to liver tissue necrosis. Several cases [21-23] have described granulocytic sarcoma as the cause of obstructive jaundice which could be another mechanism of ALF in acute myeloid leukaemia. Even though our patient had mass-like lesions on imaging, the histologic examination revealed a diffuse involvement of the hepatic and splenic tissue. The diagnosis of ALF due to AML is generally made by liver biopsy or by autopsy. While AML can present without circulating blasts, blasts on peripheral smear would typically point to the diagnosis of AML. In our case, none of the laboratory blood counts reported the presence of blasts, and even when rare peripheral blasts were noted by a haematology consultant, these were not detected by flow cytometry. Nevertheless, even if the diagnosis could have been made in a more timely fashion, this condition still engenders very high mortality. In the two previously mentioned case studies [4, 5], mortality rate was 100%. In case reports, only two out of eight patients survived after chemotherapy.

Conclusion

Even though AML as a cause of obstructive jaundice or ALF is rare, it should be considered as differential if patients have abnormal complete blood count (CBC) and hepatic or splenic enlargement. Peripheral smears should be done first in a timely manner if abnormal CBC is present. If unexplained abnormalities are present on peripheral smears in the setting of abnormal CBC and hepatomegaly or splenomegaly, bone marrow or liver biopsy should not be delayed to rapidly establish a diagnosis and timely initiate chemotherapy which would afford the patient some reasonable chance of remission and survival.

Funding

No funding was received for this case report.

Conflicts of interest

The authors declare that they have no conflicts of interest.
  23 in total

1.  Jaundice and acute liver failure as the first manifestation of acute myeloid leukemia.

Authors:  Alon Eisen; Zamir Dovrish; Ruth Hadari; Sylvia Lew; Howard Amital
Journal:  Isr Med Assoc J       Date:  2008-10       Impact factor: 0.892

Review 2.  Acute liver failure due to natural killer-like T-cell leukemia/lymphoma: a case report and review of the literature.

Authors:  Evan S Dellon; Shannon R Morris; Wozhan Tang; Cherie H Dunphy; Mark W Russo
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

3.  Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases.

Authors:  D Rowbotham; J Wendon; R Williams
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

4.  [Acute lymphatic leukemia presenting in fatal fulminant hepatitis].

Authors:  Andrea Suso; Alejandro Sola; Liliana Osay; Adriana Moreno; Adrián Salvatore; José Carena
Journal:  Medicina (B Aires)       Date:  2014       Impact factor: 0.653

5.  Relapse of acute myelogenous leukemia presenting with extrahepatic obstruction of the biliary tract.

Authors:  D P Lillicrap; A D Ginsburg; W E Corbett
Journal:  Can Med Assoc J       Date:  1982-11-15       Impact factor: 8.262

6.  Acute liver failure as the initial manifestation of acute leukaemia.

Authors:  S H Anderson; P Richardson; J Wendon; A Pagliuca; B Portmann
Journal:  Liver       Date:  2001-08

7.  Acute myeloid leukemia presenting as obstructive jaundice.

Authors:  G Rajesh; Shine Sadasivan; K R Hiran; R Nandakumar; V Balakrishnan
Journal:  Indian J Gastroenterol       Date:  2006 Mar-Apr

8.  Adult T-cell leukemia presenting with acute liver failure.

Authors:  Nicholas Powell; Ferry Rusli; Stefan G Hubscher; Mamatha Karanth; David Mutimer
Journal:  Leuk Res       Date:  2006-03-03       Impact factor: 3.156

9.  T cell prolymphocytic leukemia: a rare cause of acute liver failure.

Authors:  David P McElreath; Terence L Angtuaco; Brent Staggs; Arshad H Malik
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.487

10.  Liver involvement with acute myeloid leukemia.

Authors:  Emily Mathews; Timothy Laurie; Kenneth O'Riordan; Chadi Nabhan
Journal:  Case Rep Gastroenterol       Date:  2008-03-14
View more
  2 in total

1.  Acute Myeloid Leukemia Masquerading as Decompensated Cirrhosis.

Authors:  Hardeep S Ahdi; Seetharam Mannem; Asif Lakha
Journal:  Cureus       Date:  2022-07-31

2.  Acute hepatitis-like presentation with cholestasis of CBFB-MYH11-positive acute myeloid leukemia in an adult male: a case report.

Authors:  Irene Spinelli; Adriano De Santis; Laura Cesini; Mara Riminucci; Alessandro Corsi; Mariana Forlino; Elio Pietro Perrone; Clara Minotti; Claudio Cartoni
Journal:  J Med Case Rep       Date:  2022-07-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.